Calamos Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Calamos Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-277,808	Closed	-$16.3M	–	1068
2023 Q4	$16.3M	Buy	+277,808	New	+$15.6M	0.08%	294
2021 Q1	–	Sell	-13,103	Closed	-$2.88M	–	980
2020 Q4	$2.88M	Sell	13,103 -6,433	-33%	-$1.39M	0.02%	593
2020 Q3	$3.24M	Buy	+19,536	New	+$2.67M	0.02%	522

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Calamos Advisors's MRTX Position: Q1 2024 in Review

Calamos Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 277,808 shares — an estimated $16.3M sold.

Calamos Advisors first reported a position in MRTX in Q3 2020 and held it in 3 quarters. The position peaked at $16.3M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Calamos Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Calamos Advisors sold 277,808 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $16.3M.
Calamos Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
Calamos Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $16.3M in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Calamos Advisors's 13F filing for Q1 2024, filed 8 May 2024.